[Form 3] Vera Therapeutics, Inc. Initial Statement of Beneficial Ownership
Rhea-AI Filing Summary
Vera Therapeutics’ Chief Commercial Officer, Skelton Laurence Matthew, has filed an initial ownership report showing equity-based incentives in the company. He holds 30,000 and 15,800 shares of Class A Common Stock underlying restricted stock units that vest in tranches from November 2026 through February 2029, subject to continued service.
He also holds stock options for 60,000 shares at an exercise price of $41.75 expiring on 10/01/2034 and 31,500 shares at $29.18 expiring on 02/17/2035. These options vest monthly over time, following initial partial vesting completed in January 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Skelton Laurence Matthew
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 91,500 shares (Direct);
Class A Common Stock — 45,800 shares (Direct)
Footnotes (4)
- F1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs"). One-fourth of the RSUs vested on November 20, 2025, and the remaining three-fourths will vest in equal installments on each of November 20, 2026, 2027 and 2028, subject to the Reporting Person's continuous service through each vesting date.
- F2. Represents the number of shares of Class A Common Stock underlying the RSUs. One-fourth of the RSUs vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date.
- F3. One-third of the shares subject to the stock option vested through January 30, 2026, and 1/48 of the shares vest on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F4. 11/48 of the shares subject to the stock option vested through January 18, 2026 and 1/48 of the shares vest on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
